The invention relates to the use of an expression vector construction coding for the functional HLA-DPal03ß401 complex specifically identified by anti-HLA-DP antibodies, in order to create transgenic mice.

To explain the mechanisms of inclusion of the products of the HLA-complex in the pathogenesis of diseases several hypotheses were put forward:

A radiopharmaceutical for locating a diseased tissue (18) which forms an HLA-antigen complex (20) is also described, which radiopharmaceutical comprises such a peptide (1).

Those who inherit tissue type Major histocompatibility complex (MHC) antigen HLA-DR4 (most specifically DR0401 and 0404) are more at risk of developing rheumatoid arthritis.

In other words, there is no proof of variation in the genes in the HLA complex providing sufficient resistance to the HIV to generate an advantage, as the genetic effects outweigh the medication, treatment and prevention.